Table 1.
ATRA combination therapies reported in ClinicalTrials.gov (January 2014).
| Grants.gov ID | AML Subtype | Drug Combination | Phase |
|---|---|---|---|
| NCT00136461 | AML, MDS | ATRA and Bryostatin 1 | II |
| NCT00892190 | Refractory AML | Dasatinib, ATRA | I |
| NCT00867672 | AML | Decitabine, VPA, ATRA | II |
| NCT01575691 | AML, MDS | 5-aza-cytidine, VPA, ATRA | 1 |
| NCT00151255 | AML |
ATRA, Cytarabine, Idarubicin Mitoxantrone, Etoposide |
III |
| NCT00151242 | AML | Cytarabine, Idarubicin, Etoposide, ATRA, Pegfilgrastim | II/III |
| NCT00326170 | AML | 5-Azacytidine, VPA, ATRA | II |
| NCT01237808 | AML (NPM1 mutation) | Cytarabine, ATRA, Etoposide | III |
| NCT00143975 | Refractory AML | Cytarabine, Mitoxantrone, Gemtuzumab-Ozogamicin, ATRA | II |
| NCT00175812 | AML | Theophyllin, ATRA, VPA | I/II |
| NCT00339196 | AML, MDS | ATRA, VPA | II |
| NCT00049582 | AML, CML, MDS | Decitabine | I |
| NCT01161550 | Refractory AML | G-CSF, Cladribine, Cytarabine, ATRA, Midostaurin | I |
| NCT00995332 | AML | Cytarabine, ATRA, VPA | I |
| NCT00146120 | AML | Idarubicin, Cytosin-Arabinosid, Etoposide, ATRA | III |
| NCT00893399 | AML (with NPM1 mutation) |
ATRA, Standard chemotherapy Gemtuzumab-Ozogamicin |
III |
| NCT01369368 | AML relapse after allo- transplantation | ATRA, 5-azacitidine, VPA, hydroxurea and eventually donor leukocyte infusions. | I/II |
| NCT00615784 | AML | Bexarotene | II |
| NCT01020539 | AML, MDS, Juvenile myelomoncytic leukemia | Fludarabine, Busulfan, Graft-versus-host disease (GVHD) Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin | I |
| NCT00003405 | AML | Interferon α, Amifostine trihydrate, bromodeoxyuridine, cytarabine, idarubicin, idoxuridine, isotretinoin, mitoxantrone hydrochloride | II |
| NCT00482833 | AML | As2O3, Idarubicin, mercaptopurine, methotrexate, ATRA | III |
| NCT00217412 | Refractory cancers | SAHA, ATRA | I |
| NCT00003619 | AML, MDS, ALL, | Topotecan, fludarabine, cytarabine, and filgrastim followed by peripheral stem cell transplantation or Isotretinoin | I/II |
| NCT00006239 | AML, MDS | Sodium phenylbutyrate, Tretinoin | I |
| NCT00866073 | AML | Decitabine | II |
| NCT01987297 | AML | ATRA+ As2O3, ATRA+chemo | IV |
| NCT00413166 | APL | ATRA, As2O3, Idarubicin | II |
| NCT01409161 | APL | ATRA, As2O3, Gemtuzumab ozogamicin, Methylprednisolone | I |
| NCT00903422 | AML, MDS | Eltrombopag olamine, platelet transfusions, mild chemo, cytokines, VPA, ATRA, ESAs or G-CSF | I |
| NCT00528450 | APL | As2O3, Idarubicin, Tretinoin | II |
| NCT00002701 | APL | Busulfan, cyclophosphamide, cytarabine, etoposide, idarubicin, mercaptopurine, methotrexate, mitoxantrone hydrochloride, thioguanine, tretinoin, allogeneic/ autologous bone marrow transplantation, radiation therapy | III |
| NCT00465933 | APL | ATRA, Idarubicin | IV |
| NCT00675870 | APL | NRX 195183 synthetic retinoid | II |
| NCT00180128 | APL | ATRA, idarubicin, mitoxantrone, daunorubicin, cytarabine | IV |
| NCT01404949 | APL | Tretinoin, As2O3, | II |
| NCT01226303 | APL | ATRA, Idarubicin | III |
| NCT00520208 | APL (relapsed/refractory) | Tamibarotene (AM80) | II |
| NCT00985530 | APL | Tamibarotene, As2O3 | I |
| NCT00504764 | APL (relapsed) | As2O3, ATRA, Autologous/Allogenic transplantation, As2O3 | IV |
| NCT00196768 | APL (relapsed) | IV |